LPCN PE Ratio & Valuation,Is LPCN Overvalued

LPCN Relative Valuation

LPCN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LPCN is overvalued; if below, it's undervalued.

Historical Valuation

Lipocine Inc (LPCN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 106.77 is considered Overvalued compared with the five-year average of -4.74. The fair price of Lipocine Inc (LPCN) is between 1.01 to 2.85 according to relative valuation methord. Compared to the current price of 7.51 USD , Lipocine Inc is Overvalued By 163.6%.

Relative Value

Fair Zone

1.01-2.85

Current Price：7.51

163.6%

Overvalued

-3.36

0.00

EV/EBITDA

Lipocine Inc. (LPCN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -0.46, Undervalued between -0.46 and -0.19, Fairly Valued between 0.35 and -0.19, Overvalued between 0.35 and 0.63, and Strongly Overvalued above 0.63. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.29

EV/EBIT

Lipocine Inc. (LPCN) has a current EV/EBIT of -2.29. The 5-year average EV/EBIT is -2.04. The thresholds are as follows: Strongly Undervalued below -8.90, Undervalued between -8.90 and -5.47, Fairly Valued between 1.38 and -5.47, Overvalued between 1.38 and 4.81, and Strongly Overvalued above 4.81. The current Forward EV/EBIT of -2.29 falls within the Historic Trend Line -Fairly Valued range.

106.77

Lipocine Inc. (LPCN) has a current PS of 106.77. The 5-year average PS is 18.11. The thresholds are as follows: Strongly Undervalued below -20.26, Undervalued between -20.26 and -1.07, Fairly Valued between 37.29 and -1.07, Overvalued between 37.29 and 56.47, and Strongly Overvalued above 56.47. The current Forward PS of 106.77 falls within the Strongly Overvalued range.

-4.80

P/OCF

Lipocine Inc. (LPCN) has a current P/OCF of -4.80. The 5-year average P/OCF is -7.05. The thresholds are as follows: Strongly Undervalued below -31.00, Undervalued between -31.00 and -19.02, Fairly Valued between 4.92 and -19.02, Overvalued between 4.92 and 16.89, and Strongly Overvalued above 16.89. The current Forward P/OCF of -4.80 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Lipocine Inc. (LPCN) has a current P/FCF of 0.00. The 5-year average P/FCF is 4.76. The thresholds are as follows: Strongly Undervalued below -35.80, Undervalued between -35.80 and -15.52, Fairly Valued between 25.04 and -15.52, Overvalued between 25.04 and 45.31, and Strongly Overvalued above 45.31. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Lipocine Inc (LPCN) has a current Price-to-Book (P/B) ratio of 3.07. Compared to its 3-year average P/B ratio of 1.05 , the current P/B ratio is approximately 192.73% higher. Relative to its 5-year average P/B ratio of 1.79, the current P/B ratio is about 71.69% higher. Lipocine Inc (LPCN) has a Forward Free Cash Flow (FCF) yield of approximately -11.59%. Compared to its 3-year average FCF yield of -36.70%, the current FCF yield is approximately -68.41% lower. Relative to its 5-year average FCF yield of -25.77% , the current FCF yield is about -55.01% lower.

3.07

P/B

Median3y

1.05

Median5y

1.79

-11.59

FCF Yield

Median3y

-36.70

Median5y

-25.77

Competitors Valuation Multiple

The average P/S ratio for LPCN's competitors is 33.44, providing a benchmark for relative valuation. Lipocine Inc Corp (LPCN) exhibits a P/S ratio of 106.77, which is 219.3% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of LPCN increased by 74.07% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 114.57K.

The secondary factor is the Margin Expansion, contributed 11982.80%to the performance.

Overall, the performance of LPCN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 114.57K

Revenue Growth

11982.80%

-23.02 → -2.78K

Margin Expansion

NaN%

0.00 → -7.84

P/E Change

74.07%

4.32 → 7.52

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Lipocine Inc (LPCN) currently overvalued or undervalued?

What is Lipocine Inc (LPCN) fair value?

LPCN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lipocine Inc (LPCN) is between 1.01 to 2.85 according to relative valuation methord.

How does LPCN's valuation metrics compare to the industry average?

The average P/S ratio for LPCN's competitors is 33.44, providing a benchmark for relative valuation. Lipocine Inc Corp (LPCN) exhibits a P/S ratio of 106.77, which is 219.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Lipocine Inc (LPCN) as of Jan 08 2026?

As of Jan 08 2026, Lipocine Inc (LPCN) has a P/B ratio of 3.07. This indicates that the market values LPCN at 3.07 times its book value.

What is the current FCF Yield for Lipocine Inc (LPCN) as of Jan 08 2026?

As of Jan 08 2026, Lipocine Inc (LPCN) has a FCF Yield of -11.59%. This means that for every dollar of Lipocine Inc’s market capitalization, the company generates -11.59 cents in free cash flow.

What is the current Forward P/E ratio for Lipocine Inc (LPCN) as of Jan 08 2026?

As of Jan 08 2026, Lipocine Inc (LPCN) has a Forward P/E ratio of -3.36. This means the market is willing to pay $-3.36 for every dollar of Lipocine Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lipocine Inc (LPCN) as of Jan 08 2026?

As of Jan 08 2026, Lipocine Inc (LPCN) has a Forward P/S ratio of 106.77. This means the market is valuing LPCN at $106.77 for every dollar of expected revenue over the next 12 months.

LPCN Valuation